• 1  McCarty MA, Garton RA, Jorizzo JL. Complex aphthosis and Behçet's disease. Dermatol Clin 2003;21:418.
  • 2  Suzuki Kurokawa M, Suzuki N. Behçet's disease. Clin Exp Med 2004;4:1020. Cross Ref link Pubmed link
  • 3  Zouboulis CC. Epidemiology of Adamantiades–Behçet's disease. In: Zierhut M, Ohno S, eds. Immunology of Behçet's Disease. Lisse: Swets and Zeitlinger, 2003:116.
  • 4  Altenburg A, Papoutsis N, Orawa H, et al. Epidemiology and clinical manifestations of Adamantiades–Behçet disease in Germany – current pathogenetic concepts and therapeutic possibilities. J Dtsch Dermatol Ges 2006;4:4966. Cross Ref link Pubmed link
  • 5  Kim DY, Choi MJ, Cho S, et al. Changing clinical expression of Behçet disease in Korea during three decades (1983–2012): chronological analysis of 3674 hospital‐based patients. Br J Dermatol 2014;170:45861. Cross Ref link Pubmed link
  • 6  Zouboulis CC, May T. Pathogenesis of Adamantiades–Behçet's disease. Med Microbiol Immunol 2003;192:14955. Cross Ref link Pubmed link
  • 7  Hirohata S, Kikutchi H. Behçet's disease. Arthritis Res Ther 2003;5:13946. Cross Ref link Pubmed link
  • 8  Jorizzo JL, Abernethy JL, White WL, et al. Mucocutaneous criteria for the diagnosis of Behçet's disease: an analysis of clinicopathologic data from multiple international centers. J Am Acad Dermatol 1995;32:96876. Cross Ref link Pubmed link
  • 9  Kaneko, F, Tojo M, Sato, M, et al. The role of infectious agents in the pathogenesis of Behçet's disease. Adv Exp Med Biol 2003;528:1813. Cross Ref link Pubmed link
  • 10  Cho S, Zheng Z, Cho SB, et al. Streptococcus sanguinis and the sera of patients with Behçet's disease stimulate membrane expression of α‐enolase in human dermal microvascular endothelial cells. Arch Dermatol Res 2013;305:22332. Cross Ref link Pubmed link
  • 11  Zouboulis CC, Turnbull JR, Mühlradt PF. High seroprevalence of anti‐Mycoplasma fermentans antibodies in patients with malignant aphthosis. J Invest Dermatol 2003;121:21112. Cross Ref link Pubmed link
  • 12  Liu X, Wang C, Ye Z, et al. Higher expression of Toll‐like receptors 2, 3, 4, and 8 in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013;54:601217. Cross Ref link Pubmed link
  • 13  De Menthon M, Lavalley MP, Maldini C, et al. HLA‐B51/B5 and the risk of Behçet's disease: a systematic review and meta‐analysis of case‐control genetic association studies. Arthritis Rheum 2009;61:128796. Cross Ref link Pubmed link
  • 14  Zouboulis CC, Turnbull JR, Martus P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades–Behçet's disease. Adv Exp Med Biol 2003;528:1236. Cross Ref link Pubmed link
  • 15  Fietta P. Behçet's disease: familial clustering and immunogenetics. Clin Exp Rheumatol 2005;23(Suppl. 38):S96105. Pubmed link
  • 16  Durrani K, Papaliodis GN. The genetics of Adamantiades–Behcet's disease. Semin Ophthalmol 2008;23:739. Cross Ref link Pubmed link
  • 17  Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet's disease. Cell Mol Life Sci 2003;60:190322. Cross Ref link Pubmed link
  • 18  Remmers EF, Cosan F, Kirino Y, et al. Genome‐wide association study identifies variants in the MHC class I, IL10, and IL23R‐IL12RB2 regions associated with Behçet's disease. Nat Genet 2010;42:698702. Cross Ref link Pubmed link
  • 19  Papoutsis N, Bonitsis N, Altenburg A, et al. HLA‐antigens and their importance as prognostic‐marker in Adamantiades–Behçet's disease (ABD) – is HLA‐Bw4 a new prognostic marker? Abstracts of the 14th International Conference on Behçet's disease, London, 2010:163.
  • 20  Escudier M, Bagan J, Scully C. Behçet's disease (Adamantiades syndrome). Oral Dis 2006;12:7884. Cross Ref link Pubmed link
  • 21  Mizuki N, Meguro A, Ota M, et al. Genome‐wide association studies identify IL23R‐IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010;42:7036. Cross Ref link Pubmed link
  • 22  Lee EB, Kim JY, Zhao J, et al. Haplotype association of IL‐8 gene with Behcet's disease. Tissue Antigens 2007;69:12832. Cross Ref link Pubmed link
  • 23  Jiang Z, Yang P, Hou S, et al. IL‐23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis 2010;69:13258. Cross Ref link Pubmed link
  • 24  Hatemi G, Seyahi E, Fresko I, et al. Behçet's syndrome: a critical digest of the 2012–2013 literature. Clin Exp Rheumatol 2013;31(Suppl. 77):10817. Pubmed link
  • 25  Gül A. Behçet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005;4:813. Cross Ref link Pubmed link
  • 26  Yanagihori H, Oyama N, Nakamura K, et al. Role of IL‐12B promoter polymorphism in Adamantiades–Behçet's disease susceptibility: an involvement of Th1 immunoreactivity against streptococcus sangunis antigen. J Invest Dermatol 2006;126:153440. Cross Ref link Pubmed link
  • 27  Freysdottir J, Hussain L, Farmer I, et al. Diversity of γδ T cells in patients with Behçet's disease is indicative of polyclonal activation. Oral Dis 2006;12:2717. Cross Ref link Pubmed link
  • 28  Mahesh SP, Li Z, Buggage R, et al. Alpha tropomyosin as a self‐antigen in patients with Behçet's disease. Clin Exp Immunol 2005;140:36875. Cross Ref link Pubmed link
  • 29  Lu Y, Ye P, Chen S‐L, et al. Identification of kinectin as a novel Behçet's disease autoantigen. Arthritis Res Ther 2005;7:R11339. Cross Ref link Pubmed link
  • 30  Direskeneli H, Saruhan‐Direskeneli G. The role of heat shock proteins in Behçet's disease. Clin Exp Rheumatol 2003;21:S448. Pubmed link
  • 31  Birtas‐Atesoglu E, Inanc N, Yavuz S, et al. Serum levels of free heat shock protein 70 and anti‐HSP70 are elevated in Behçet's disease. Clin Exp Rheumatol 2008;26(Suppl. 50):S968. Pubmed link
  • 32  Katsantonis J, Adler Y, Orfanos CE, et al. Adamantiades–Behçet's disease: serum IL‐8 is a more reliable marker for disease activity than c‐reactive protein and erythrocyte sedimentation rate. Dermatology 2000;201:379. Cross Ref link Pubmed link
  • 33  Durmazlar SP, Ulkar GB, Eskioglu F, et al. Significance of serum interleukin‐8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009;48:25964. Cross Ref link Pubmed link
  • 34  Polat M, Vahaboglu G, Onde U, et al. Classifying patients with Behçet's disease for disease severity, using a discriminating analysis method. Clin Exp Dermatol 2009;34:1515. Cross Ref link Pubmed link
  • 35  Chi W, Zhu X, Yang P, et al. Upregulated IL‐23 and IL‐17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008;49:305864. Cross Ref link Pubmed link
  • 36  Habibagahi Z, Habibagahi M, Heidari M. Raised concentration of soluble form of vascular endothelial cadherin and IL‐23 in sera of patients with Behçet's disease. Mod Rheumatol 2010;20:1549. Cross Ref link Pubmed link
  • 37  Na SY, Park MJ, Park S, et al. Up‐regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity. Clin Exp Rheumatol 2013;31(Suppl. 77):3240. Pubmed link
  • 38  Cai T, Wang Q, Zhou Q, et al. Increased expression of IL‐22 is associated with disease activity in Behcet's disease. PLOS One 2013;8:e59009. Cross Ref link Pubmed link
  • 39  Sugita S, Kawazoe Y, Imai A, et al. Role of IL‐22‐ and TNF‐α‐producing Th22 cells in uveitis patients with Behçet's disease. J Immunol 2013;190:5799808. Cross Ref link Pubmed link
  • 40  Kim D‐J, Baek S‐Y, Park M‐K, et al. Serum level of interleukin‐33 and soluble ST2 and their association with disease activity in patients with Behcet's disease. J Korean Med Sci 2013;28:114553. Cross Ref link Pubmed link
  • 41  Kalayciyan A, Zouboulis CC. An update on Behçet's disease. J Eur Acad Dermatol Venereol 2007;21:110. Cross Ref link Pubmed link
  • 42  Lee KH, Chung HS, Kim HS, et al. Human alpha‐enolase from endothelial cells as a target antigen of anti‐endothelial cell antibody in Behçet's disease. Arthritis Rheum 2003;48:202535. Cross Ref link Pubmed link
  • 43  Zouboulis CC, Keitel W. A historical review of early descriptions of Adamantiades–Behçet's disease. J Invest Dermatol 2002;119:2015. Cross Ref link Pubmed link
  • 44  International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:107880. Pubmed link
  • 45  Kaneko F, Oyama T, Sato M, et al. Behçet's Disease and Diseases for its Differential Diagnosis in Dermatology. Annual Report of the Behçet's Disease Research Committee of Japan. Tokyo: Behçet's Disease Research Committee of Japan, 1999.
  • 46  International Team for the Revision of the International Criteria for Behçet's Disease (ITR‐ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2013;28:33847. Pubmed link
  • 47  Oh SH, Han EC, Lee JH, et al. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease. Clin Exp Dermatol 2009;34:e20812. Cross Ref link Pubmed link
  • 48  Krause L. Morbus Adamantiades–Behcet. Ophthalmologe 2005;102:32934. Cross Ref link Pubmed link
  • 49  Rogers RS, 3rd. Pseudo‐Behçet's disease. Dermatol Clin 2003;21:4961. Cross Ref link Pubmed link
  • 50  Zouboulis CC, Kötter I, Djawari D, et al. Current epidemiological data from the German Registry of Adamantiades–Behçet's disease. Adv Exp Med Biol 2003;528:438. Cross Ref link Pubmed link
  • 51  Sakamoto M, Akazawa K, Nisioka Y, et al. Prognostic factors of vision in patients with Behçet disease. Ophthalmology 1995;102:31721. Cross Ref link Pubmed link
  • 52  Coskun B, Öztürk P, Saral Y. Are erythema nodosum‐like lesions and superficial thrombophlebitis prodromal in terms of visceral involvement in Behçet's disease? Int J Clin Pract 2005;59:6971. Cross Ref link Pubmed link
  • 53  Cingu AK, Onal S, Urgancioglu M, et al. Comparison of presenting features and three‐year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 2012;20:4238. Cross Ref link Pubmed link
  • 54  Bonitsis NG, Altenburg A, Krause L, et al. Current concepts in the treatment of Adamantiades–Behçet's disease. Drugs Fut 2009;34:74963. Cross Ref link
  • 55  Zouboulis CC. Adamantiades–Behçet's disease. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatments, 2nd edn. Berlin: Springer, 2003:1626. Cross Ref link
  • 56  Alpsoy E. New evidence‐based treatment approach in Behçet's disease. Pathol Res Intern 2012;2012:871019.
  • 57  Altenburg A, Abdel‐Naser B, Abdallah M, et al. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007;21:101926. Cross Ref link Pubmed link
  • 58  Lee JH, Jung JY, Bang D. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behçet's disease. J Eur Acad Dermatol Venereol 2008;22:5905. Cross Ref link Pubmed link
  • 59  Atmaca LS, Yalçindağ FN, Ozdemir O. Intravitreal triamcinolone acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol 2007;245:4516. Cross Ref link Pubmed link
  • 60  Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther 2007;23:395401. Cross Ref link Pubmed link
  • 61  Altenburg A, Micheli CK, Maldini C, et al. Klinik und Therapie chronisch rezidivierender Aphthen. Hautarzt 2012;63:693703. Cross Ref link Pubmed link
  • 62  Pipitone N, Olivieri I, Cantini F, et al. New approaches in the treatment of Adamantiades–Behçet's disease. Curr Opin Rheumatol 2006;18:39. Cross Ref link Pubmed link
  • 63  Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence‐based recommendations for the management of Behçet disease. Ann Rheum Dis 2009;68:152834. Cross Ref link Pubmed link
  • 64  Comarmond C, Wechsler B, Cacoub P, et al. Traitement de la maladie de Behçet. Rev méd interne 2014;3512638.
  • 65  Mat C, Yurdakul S, Uysal S, et al. A double‐blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006;45:34852. Cross Ref link Pubmed link
  • 66  Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double‐blind, placebo‐controlled study. Drugs R D 2003;4:1928. Cross Ref link Pubmed link
  • 67  Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet's disease: randomized, double‐blind, controlled crossover trial. Mod Rheumatol 2009;19:5429. Cross Ref link Pubmed link
  • 68  Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399402. Pubmed link
  • 69  Yurdakul S, Mat C, Tüzün Y, et al. A double‐blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001;44:268692. Cross Ref link Pubmed link
  • 70  Hamuryudan V, Hatemi G, Tascilar K, et al. Colchicine in Behcet syndrome: a longterm survey of patients in a controlled trial. J Rheumatol 2014;41:7358. Cross Ref link Pubmed link
  • 71  Çalgüneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996;192:1258. Cross Ref link Pubmed link
  • 72  Al‐Waiz MM, Sharquie KE, A‐Qaissi MH, et al. Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study. Dermatology Online J 2005;11(3):3.
  • 73  Sharquie KE, Najim RA, Al‐Dori WS, et al. Oral zinc sulfate in the treatment of Behçet's disease: a double blind cross‐over study. J Dermatol 2006;33:5416. Cross Ref link Pubmed link
  • 74  Sharquie KE, Najim RA, Abu‐Raghif AR. Dapsone in Behçet's disease: a double‐blind, placebo‐controlled, cross‐over study. J Dermatol 2002;29:26779. Cross Ref link Pubmed link
  • 75  Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's disease. N Engl J Med 1990;322:2815. Cross Ref link Pubmed link
  • 76  Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa‐2a in the treatment of Behçet's disease: a randomized placebo‐controlled and double‐blind study. Arch Dermatol 2002;138:46771. Cross Ref link Pubmed link
  • 77  Kiliç H, Zeytin HE, Korkmaz C, et al. Low‐dose natural human interferon‐alpha lozenges in the treatment of Behçet's syndrome. Rheumatology (Oxford) 2009;48:138891. Cross Ref link Pubmed link
  • 78  Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double‐blind, placebo‐controlled trial. Ann Intern Med 1998;128:44350. Cross Ref link Pubmed link
  • 79  Masuda K, Nakajima A, Urayama A, et al. Double‐masked trial of cyclosporin versus colchicine and long‐term open study of cyclosporin in Behçet's disease. Lancet 1989;1(8647):10936. Cross Ref link Pubmed link
  • 80  BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 1988;20(Suppl. 4):13643. Pubmed link
  • 81  Elidan J, Cohen E, Levi H, et al. Effect of cyclosporine A on the hearing loss in Behçet's disease. Ann Otol Rhinol Laryngol 1991;1004648.
  • 82  Assaad‐Khalil SH. Low‐dose cyclosporin in Behçet's disease: follow‐up controlled study with emphasis on extraocular manifestations and neuro‐Behçet's disease. In: O'Duffy JD, Kokmen E, eds. Behçet's Disease: Basic and Clinical Aspects. New York: Marcel Dekker, 1991:60312.
  • 83  Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol 1992;76:2413. Cross Ref link Pubmed link
  • 84  Davatchi F, Shahram F, Chams H, et al. Pulse cyclophosphamide (PCP) for ocular lesions of Behçet's disease: double blind crossover study. Arthritis Rheum 1999;42:S320.
  • 85  Melikoglu M, Fresko I, Mat C, et al. Short‐term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98105. Pubmed link
  • 86  Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behçet's disease; randomized single‐blind control study (pilot study). Int J Rheum Dis 2010;13:24652. Cross Ref link Pubmed link
  • 87  Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet's syndrome: a randomized double‐blind trial. Br J Rheumatol 1998;27:3002. Cross Ref link
  • 88  Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behcet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995;13:4935. Pubmed link
  • 89  Buggage RR, Levy‐Clarke G, Sen HN, et al. A double‐masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm 2007;15:6370. Cross Ref link Pubmed link
  • 90  Nanke Y, Kamatani N, Okamoto T, et al. Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease: an open‐label, single‐centre study. Drugs R D 2008;9:4559. Cross Ref link Pubmed link
  • 91  Zouboulis, CC. Morbus Adamantiades–Behçet. In: Mrowietz U, ed. Ciclosporin in der Dermatologie. Stuttgart: Thieme, 2003:3851.
  • 92  Yasui K, Uchida N, Akazawa Y, et al. Thalidomide for treatment of intestinal involvement of juvenile‐onset Behçet disease. Inflamm Bowel Dis 2008;14:396400. Cross Ref link Pubmed link
  • 93  Zouboulis CC, Orfanos CE. Treatment of Adamantiades–Behçet's disease with systemic interferon alfa. Arch Dermatol 1998;134:101016. Cross Ref link Pubmed link
  • 94  Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades–Behçet's disease treated with interferon‐alpha‐2a. J Rheumatol 2008;35:896903. Pubmed link
  • 95  Guillaume‐Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon‐alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 2007;46:15703. Cross Ref link Pubmed link
  • 96  Davatchi F, Sadeghi Abdollahi B, Shams H, et al. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years. Int J Rheum Dis 2014;17:44452. Cross Ref link Pubmed link
  • 97  Davatchi F, Shams H, Shahram F, et al. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years. Int J Rheum Dis 2013;16:56877. Cross Ref link Pubmed link
  • 98  Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti‐TNF therapy in the management of Behçet's disease: review and basis for recommendations. Rheumatology (Oxford) 2007;46:73641. Cross Ref link Pubmed link
  • 99  Niccoli L, Nannini C, Benucci M, et al. Long‐term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24‐month follow‐up study. Rheumatology (Oxford) 2007;46:11614. Cross Ref link Pubmed link
  • 100  Tognon S, Graziani G, Marcolongo R. Anti‐TNF‐alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann NY Acad Sci 2007;1110:47484. Cross Ref link Pubmed link
  • 101  Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro‐Behçet's disease: a case series and review of the literature. Arthritis Rheum 2008;59:28590. Cross Ref link Pubmed link
  • 102  Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 2008;14:125964. Cross Ref link Pubmed link
  • 103  Sakai T, Watanabe H, Kuroyanagi K, et al. Health‐ and vision‐related quality of life in patients receiving infliximab therapy for Behcet uveitis. Br J Ophthalmol 2013;97:33842. Cross Ref link Pubmed link
  • 104  Ha LJ, Hee CJ, Woo JS, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 2013;19:18338. Pubmed link
  • 105  Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients. Rheumatology 2012;51:182531. Cross Ref link Pubmed link
  • 106  Gül A, Tugal‐Tutkun I, Dinarello CA, et al. Interleukin‐1‐regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open‐label pilot study. Ann Rheum Dis 2012;71:5636. Pubmed link